Commercial anti-CD19 CAR T cell therapy fo patients with relapsed/refractory aggressive B cell lymphoma in a European center.

Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA number for access, including all letters and numbers. This number is stored to enable your ongoing access to the site but no other personal details are retained. To view our full Privacy Policy please click here.